Tiagabine
📖 About
Always check the BNF link here before prescribing.
- 💊 Tiagabine is an anticonvulsant used as adjunctive therapy.
- Not used as monotherapy; reserved for partial seizures uncontrolled by first-line agents.
⚙️ Mode of Action
- Blocks neuronal GABA reuptake (GAT-1 inhibitor).
- ➡️ Increases extracellular GABA concentration → enhanced inhibitory neurotransmission.
📋 Indications
- Adjunctive treatment of partial seizures with or without secondary generalisation.
- Not licensed for primary generalised epilepsy.
💊 Dose
- Start: 4–5 mg OD, increase gradually every 1–2 weeks.
- Maintenance: 15–30 mg/day in divided doses (usually TDS).
- Higher doses may be required in patients on enzyme inducers (e.g. carbamazepine, phenytoin).
🔄 Interactions
- See BNF for full list.
- Metabolised by CYP3A4 → levels affected by inducers/inhibitors.
- Other CNS depressants (benzodiazepines, alcohol) → additive sedation, dizziness.
⛔ Contraindications / Cautions
- Not recommended in absence or myoclonic seizures (may worsen).
- Caution in hepatic impairment (hepatic metabolism).
- Psychiatric history – can exacerbate depression, psychosis, or suicidal ideation.
⚠️ Side Effects
- 🌀 Dizziness, ataxia, tremor.
- 🛌 Tiredness, somnolence, confusion.
- 🧠 Depression, anxiety, irritability (psychiatric symptoms more common than with many other antiepileptics).
- Rare: non-convulsive status epilepticus, worsening of seizures.
📝 Clinical Pearls
- Not a first-line drug; consider in refractory partial epilepsy only.
- Titrate dose slowly to reduce risk of CNS and psychiatric side effects.
- Always monitor mood and mental health during treatment.
- Avoid abrupt withdrawal – risk of rebound seizures/status epilepticus.
📚 References